Ventyx Biosciences Inc (VTYX)
4.805
-0.18
(-3.51%)
USD |
NASDAQ |
May 20, 16:00
4.805
0.00 (0.00%)
After-Hours: 16:15
Ventyx Biosciences Cash from Operations (TTM): -183.23M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -183.23M |
| December 31, 2023 | -166.52M |
| September 30, 2023 | -162.13M |
| June 30, 2023 | -151.46M |
| March 31, 2023 | -116.97M |
| Date | Value |
|---|---|
| December 31, 2022 | -98.77M |
| September 30, 2022 | -66.19M |
| June 30, 2022 | -53.25M |
| March 31, 2022 | -48.36M |
| December 31, 2021 | -38.65M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-183.23M
Minimum
Mar 2024
-38.65M
Maximum
Dec 2021
-108.55M
Average
-107.87M
Median
Cash from Operations (TTM) Benchmarks
| Anavex Life Sciences Corp | -32.48M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | -14.43M |
| Checkpoint Therapeutics Inc | -40.03M |
| RAPT Therapeutics Inc | -105.53M |